News & Resources

Overview

Corporate Profile

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Orexigen developed Contrave® (naltrexone HCl and bupropion HCl extended release), which is approved in the United States and is being commercialized there by the companys North American partner, Takeda Pharmaceuticals. In Europe the drug has been approved under the brand name Mysimba™ (naltrexone HCl/ bupropion HCl prolongedMore >>

Stock Quote

OREX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$1.65
Change (%) Stock is Up 0.04 (2.48%)
Volume891,027
Feb 10, 2016 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent News

More >>
DateTitle 
02/02/16Orexigen Therapeutics to Speak at Upcoming Investor ConferencesPrinter Friendly Version
01/11/16Orexigen announces 2016 financial outlook and key prioritiesPrinter Friendly Version
01/08/16Orexigen Therapeutics names Thomas Lynch as EVP, General Counsel & Secretary and Heather Ace as EVP, Global Human ResourcesPrinter Friendly Version
01/05/16Orexigen Therapeutics to Speak at the J.P. Morgan 2016 Global Healthcare ConferencePrinter Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.